Does acute treatment with sedatives/hypnotics for anxiety in depressed patients affect suicide risk? A literature review

Annals of Clinical Psychiatry

Volumn 20, Issue 3, 2008, Pages 157-169

  Youssef, Nagy A ^a   Rich, Charles L ^b  

^a UNIVERSITY OF SOUTH ALABAMA   (United States)

^b NONE   (United States)

Author keywords

Anxiety; Depression; Disinhibition; Hypnotics; Sedatives; Suicide

Indexed keywords

ALPRAZOLAM; ANTIDEPRESSANT AGENT; ARIPIPRAZOLE; BUSPIRONE; CHLORDIAZEPOXIDE; DIAZEPAM; FLUMAZENIL; GABAPENTIN; HYDROXYZINE; HYPNOTIC AGENT; OLANZAPINE; PREGABALIN; QUETIAPINE; RISPERIDONE; SEDATIVE AGENT; TIAGABINE; VALPROATE SEMISODIUM; ZIPRASIDONE;

ANXIETY DISORDER; BEDTIME DOSAGE; BEHAVIOR THERAPY; BIPOLAR DEPRESSION; COGNITIVE THERAPY; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIZZINESS; DROWSINESS; DRUG DOSE INCREASE; DRUG DOSE TITRATION; FOOD AND DRUG ADMINISTRATION; HAMILTON SCALE; HUMAN; MAJOR DEPRESSION; MEDICAL LITERATURE; MEDLINE; OBSESSIVE COMPULSIVE DISORDER; OFF LABEL DRUG USE; PANIC; PRIORITY JOURNAL; PUBLICATION; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SOMNOLENCE; SUICIDAL IDEATION; SUICIDE ATTEMPT; TREMOR;

ANTIDEPRESSIVE AGENTS; ANXIETY DISORDERS; DEPRESSIVE DISORDER; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; HUMANS; HYPNOTICS AND SEDATIVES; RISK; SUICIDE;

EID: 47549097002     PISSN: 10401237     EISSN: 15473325     Source Type: Journal    
DOI: 10.1080/10401230802177698     Document Type: Review

References (178)

1. Isacsson G, Rich CL. Antidepressant drug use and suicide prevention. Int Rev Psychiatry. 2005;17:153-162.
2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Text Revision. Washington, DC: APA, 2000.
3. Fawcett J, Scheftner WA, Fogg L, Clark DC, Young MA, Hedeker D, Gibbons R. Time-related predictors of suicide in major affective disorder. Am J Psychiatry. 1990;147:1189-1194.
4. Valenstein M, Taylor KK, Austin K, Kales HC, McCarthy JF, Blow FC. Benzodiazepine use among depressed patients treated in mental health settings. Am J Psychiatry. 2004;161:654-661.
5. Brunton, LL. Goodman & Gilman's - The Pharmacological Basis of Therapeutics, 11th ed. New York: McGraw-Hill, 2006.
6. Craig TJ, Van Natta PA. Current medication use and symptoms of depression in a general population. Am J Psychiatry. 1978;135:1036-1039.
7. James IP. Blood alcohol levels following successful suicide. QJ Stud Alcohol. 1966;27:23-29.
8. Riddick L, Luke JL. Alcohol-associated deaths in the District of Columbia - A postmortem study. J Forensic Sci. 1978;23:493-502.
9. Norton LE, Garriott JC, DiMaio VJ. Drug detection at autopsy: A prospective study of 247 cases. J Forensic Sci. 1982;27:66-71.
10. Abel EL, Zeidenberg P. Age, alcohol and violent death: A postmortem study. J Stud Alcohol. 1985;46:228-231.
11. Berkelman RL, Herndon JL, Callaway JL, Stivers R, Howard LB, Bezjak A, Sikes RK. Fatal injuries and alcohol. Am J Prev Med. 1985;1:21-28.
12. Welte JW, Abel EL, Wieczorek W. The role of alcohol in suicides in Erie County, NY, 1972-84. Public Health Rep. 1988;103:648-652.
13. Goodman RA, Istre GR, Jordan FB, Herndon JL, Kelaghan J. Alcohol and fatal injuries in Oklahoma. J Stud Alcohol. 1991;52:156-161.
14. Kubo S, Dankwarth G, Puschel K. Blood alcohol concentrations of sudden unexpected deaths and non natural deaths. Forensic Sci Int. 1991;52:77-84.
15. Hayward L, Zubrick SR, Silburn S. Blood alcohol levels in suicide cases. J Epidemiol Community Health. 1992;46:256-260.
16. Mendelson WB, Rich CL. Sedatives and suicide: The San Diego study. Acta Psychiatr Scand 1993;88:337-341.
17. Ohberg A, Vuori E, Ojanpera I, Lonngvist J. Alcohol and drugs in suicides. Br J Psychiatry 1996;169:75-80.
18. Dhossche DM, Rich CL, Isacsson G. Psychoactive substances in suicides. Comparison of toxicologic findings in two samples. Am J Forensic Med Pathol. 2001;22:239-243.
19. Shields LBE, Hunsaker DM, Hunsaker JC, Ward MK. Toxicologic findings in suicide. A 10-year retrospective review of Kentucky medical examiner cases. Am J Forensic Med Pathol. 2006;27:106-112.
20. Isacsson G, Rich CL. Depression, antidepressants, and suicide: Pharmacoepidemiological evidence for suicide prevention. In: Maris RW, Silverman MM, Canetto SS, eds. Review of Suicidology. New York: Guilford Publications, 1997:168-201.
21. Johnstone EE, Claghorn JL. Doxepin vs. chlordiazepoxide: A controlled comparison in neurotic outpatients. Curr Ther Res Clin Exp. 1968;10:514-519.
22. Rickels K, Perloff M, Stepansky W, Dion HS, Case WG, Sapra RK. Doxepin and diazepam in general practice and hospital clinic neurotic patients: A collaborative controlled study. Psychopharmacologia. 1969;15:265-279.
23. Verner JV, Jr. Comparison of imipramine and chlordiazepoxide in the treatment of the depressed and anxious patient. J Fla Med Assoc. 1969;56:15-21.
24. Beaubien J, Ban TA, Lehman HE, Jarrold L. Doxepin in the treatment of psychoneurotic patients. Curr Ther Res Clin Exp. 1970;12:192-194.
25. Derogatis LR, Covi L, Lipman RS, Rickels K. Dimensions of outpatient neurotic pathology: Comparison of a clinical versus an empirical assessment. J Consult Clin Psychol. 1970;34:164-171.
26. Kay DW, Fahy T, Garside RF. A seven-month double-blind trial of amitriptyline and diazepam in ECT-treated depressed patients. Br J Psychiatry. 1970;117:667-671.
27. Montgomery BA, Cullinan TR, Bayley AJ. A double-blind comparative trial of doxepin hydrochloride and chlordiazepoxide in anxiety and depression in general practice. Br J Clin Pract. 1970;24:207-209.
28. Rickels K, Gordon PE, Jenkins BW, Perloff M, Sachs T, Stepansky W. Drug treatment in depressive illness. Dis Nerv Syst. 1970;31:30-42.
29. Sterlin C, Ban TA, Lehmann HE, Jarrold L. A comparative evaluation of doxepin and chlordiazepoxide in the treatment of psychoneurotic outpatients. Curr Ther Res Clin Exp. 1970;12:195-200.
30. Butterworth AT, Watts RD. Treatment of hospitalized alcoholics with doxepin and diazepam. A controlled study. QJ Stud Alcohol. 1971;32:78-81.
31. Claghorn J, Kellner R. When is a tranquillizer an antidepressant? Curr Ther Res Clin Exp. 1971;13:575-579.
32. General Practitioner Clinical Trials: Antidepressant effects of tranquilizers. Practitioner. 1971;206:146-149
33. Sim M, Bindman E, Conochie B, et al. The treatment of anxiety/depressive states. Clin Trials J. 1971;8:22-27.
34. Sterlin C, Ban TA, Jarrold L. The place of doxepin among the anxiolytic-sedative drugs. Curr Ther Res Clin Exp. 1972;14:195-204.
35. Goldstein BJ, Brauzer B, Steinbook RM, Jacobson AF. Psychotropic drug treatment of mixed anxiety and depression in nonpsychiatric office patients: Expected and unexpected findings - comparing doxepin, chlordiazepoxide and placebo. South Med J. 1973;66:892-897.
36. Johnson F, Sacco FA, Yellowley TW. Chlordiazepoxide and dothiepin compared in anxiety-depression in general practice. Practitioner. 1973;211:362-364.
37. Overall JE, Brown D, Williams JD, Neill LT. Drug treatment of anxiety and depression in detoxified alcoholic patients. Arch Gen Psychiatry. 1973;29:218-225.
38. Rickels K, Chung HR, Feldman HS, Gordon PE, Kelly EA, Weise CC. Amitriptyline, diazepam, and phenobarbital sodium in depressed outpatients. J Nerv Ment Dis. 1973;157:442-451.
39. Covi L, Lipman RS, Derogatis LR, Smith JE, III, Pattison JH. Drugs and group psychotherapy in neurotic depression. Am J Psychiatry. 1974;131:191-198.
40. d'Elia G, von Knorring L, Marcusson J, Mattsson B, Perris C, Persson G. A double blind comparison between doxepin and diazepam in the treatment of states of anxiety. Acta Psychiatr Scand Suppl. 1974;255:35-46.
41. Hare M. Treatment of anxiety and depression: A comparative trial of amitriptyline (Laroxyl) and diazepam (valium). Clin Trials J. 1974;11:39-44.
42. Magnus RV. A placebo controlled trial of viloxazine with and without tranquillizers in depressive illness. J Int Med Res. 1975;3:207-213.
43. Haskell DS, Gambill JD, Gardos G, McNair DM, Fisher S. Doxepin or diazepam for anxious and anxious-depressed outpatients? J Clin Psychiatry. 1978;39:135-139.
44. Russell GF, Niaz U, Wakeling A, Slade PD. Comparative double-blind trial of mianserin hydrochloride (Organon GB94) and diazepam in patients with depressive illness. Br J Clin Pharmacol. 1978;5(Suppl 1):57S-65S.
45. Remick RA, Fleming JA, Buchanan RA, Keller FD, Hamilton P, Loomer F, Miles JE. A comparison of the safety and efficacy of alprazolam and desipramine in moderately severe depression. Can J Psychiatry. 1985;30:597-601.
46. Tiller J, Schweitzer I, Maguire K, Davies B. A sequential double-blind controlled study of moclobemide and diazepam in patients with atypical depression. J Affect Disord. 1989;16:181-187.
47. Laws D, Ashford JJ, Anstee JA. A multicentre double-blind comparative trial of fluvoxamine versus lorazepam in mixed anxiety and depression treated in general practice. Acta Psychiatr Scand. 1990;81:185-189.
48. Ansseau M, Devoitille JM, Papart P, Vanbrabant E, Mantanus H, Timsit-Berthier M. Comparison of adinazolam, amitriptyline, and diazepam in endogenous depressive inpatients exhibiting DST nonsuppression or abnormal contingent negative variation. J Clin Psychopharmacol. 1991;11:160-165.
49. Lemoine P, Boulenger JP, Caillard V, Tanne N, Bonnet D. Compared efficacy of prazepam and clomipramine in major depression with anxiety: A multicenter controlled study. Pharmacopsychiatry. 1991;24:175-179.
50. Rickels K, London J, Fox I, Hassman H, Csanalosi I, Weise C. Adinazolam, diazepam, imipramine, and placebo in major depressive disorder: A controlled study. Pharmacopsychiatry. 1991;24:127-131.
51. Laakman G, Faltermaier-Temizel M, Bossert-Zaudig S, Baghai T, Lorkowski G. Treatment of depressive outpatients with lorazepam, alprazolam, amytriptyline and placebo. Psychopharmacology (Berl). 1995;120:109-115.
52. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry. 1960;23:56-62.
53. PDR: Physicians' Desk Reference. Montvale, NJ: Thomson PDR, 2007.
54. Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: A double-blind study. Am J Psychiatry. 1998;155:1339-1345.
55. Londborg PD, Smith WT, Glaudin V, Painter JR. Short-term cotherapy with clonazepam and fluoxetine: Anxiety, sleep disturbance, and core symptoms of depression. J Affect Disord. 2000;61:73-79.
56. Smith WT, Londborg PD, Glaudin V, Painter JR. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord. 2002;70:251-259.
57. Fawcett J. Treating impulsivity and anxiety in the suicidal patient. Ann NY Acad Sci. 2001;932:94-102; discussion 102-105.
58. Ferrari M, Barabas G, Matthews WS. Psychologic and behavioral disturbance among epileptic children treated with barbiturate anticonvulsants. Am J Psychiatry. 1983;140:112-113.
59. Barabas G, Matthews WS. Barbiturate anticonvulsants as a cause of severe depression. Pediatrics. 1899;82:284-285.
60. Brent DA, Crumrine PK, Varma RR, Allan M, Allman C. Phenoparbital treatment and major depressive disorder in children with epilepsy. Pediatrics. 1987;80:909-917.
61. Rao AV. A controlled trial with "valium" in obsessive compulsive state. J Ind Med Assoc. 1964;42:564-567.
62. Kraft IA, Ardali C, Duffy JH, Hart JT, Pearce P. A clinical study of chlordiazepoxide used in psychiatric disorders of children. Int J Neuropsych. 1965;1:433-437.
63. Gundlach R, Engelhardt DM, Hankoff L, Paley H, Rudorfer L, Byrd E. A double-blind outpatient study of diazepam (valium) and placebo. Psychopharmacologia. 1966;9:81-92.
64. McDowall A, Owen S, Robin AA. A controlled comparison of diazepam and amylobarbitone in anxiety states. Br J Psychiatry. 1966;112:629-631.
65. Ryan HF, Merrill FB, Scott GE, Krebs R, Thompson BL. Increase in suicidal thoughts and tendencies. Association with diazepam therapy. JAMA. 1968;203:1137-1139.
66. Hall RC, Joffe JR. Aberrant response to diazepam: A new syndrome. Am J Psychiatry. 1972;129:738-742.
67. Lydiard RB, Laraia MT, Ballenger JC, Howell EF. Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry. 1987;144:664-665.
68. Cohen LS, Rosenbaum JF. Clonazepam: New uses and potential problems. J Clin Psychiatry. 1987;48(Suppl):50-56.
69. Noyes R Jr, Duport RL, Pecknold JC, Rifkin A, Rubin RT, Swinson RP, Ballenger JC, Burrows GD. Alprazolam in panic disorder and agoraphobia: Results from a multicenter trial. Arch Gen Psychiatry. 1988;45:423-428.
70. O'Sullivan GH, Noshirvani H, Basoglu M, Marks IM, Swinson R, Kuch K, Kirby M. Safety and side-effects of alprazolam. Controlled study in agoraphobia with panic disorder. Br J Psychiatry. 1994;165:79-86.
71. Edwards JG, Inman WHW, Pearce GL, Rawson NSB. Prescription-event monitoring of 10,895 patients treated with alprazolam. Br J Psychiatry. 1991;158:387-392.
72. PDR: Physicians' Desk Reference. Montvale, NJ: Medical Economics Company, 1997.
73. Litchfield NB. Complications of intravenous diazepam - adverse psychological reactions. (An assessment of 16,000 cases.). Anesth Prog. 1980;28:175-183.
74. Short TG, Forrest P, Galletly DC. Paradoxical reactions to benzodiazepines - a genetically determined phenomenon? Anaesth Intens Care. 1987;15:330-331.
75. Lobo BL, Miwa LJ. Midazolam disinhibition reaction. Drug Intell Clin Pharm. 1988;22:725.
76. Rodrigo CR. Flumazenil reverses paradoxical reaction with midazolam. Anesth Prog. 1991;38:65-68.
77. Honan VJ. Paradoxical reaction to midazolam and control with flumazenil. Gastrointest Endosc. 1994;40:86-88.
78. Thakker P, Gallagher TM. Flumazenil reverses paradoxical reaction to midazolam in a child. Anaesth Intens Care. 1996;24:505-507.
79. Thurston TA, Williams CG, Foshee SL. Reversal of a paradoxical reaction to midazolam with flumazenil. Anesth Analg. 1996;83:192.
80. Khan LC, Lustik SJ. Treatment of a paradoxical reaction to midazolam with haloperidol. Anesth Analg. 1997;85:213-215.
81. Massanari M, Novitsky J, Reinstein LJ. Paradoxical reactions in children associated with midazolam use during endoscopy. Clin Pediatr (Phila). 1997;36:681-684.
82. Fulton SA, Mullen KD. Completion of upper endoscopic procedures despite paradoxical reaction to midazolam: A role for flumazenil? Am J Gastroenterol. 2000;95:809-811.
83. Saltik IN, Ozen H. Role of flumazenil for paradoxical reaction to midazolam during endoscopic procedures in children. Am J Gastroenterol. 2000;95:3011-3012.
84. Weinbroum AA, Szold O, Ogorek D, Flaishon R. The midazolam-induced paradox phenomenon is reversible by flumazenil. Epidemiology, patient characteristics and review of the literature. Eur J Anaesthesiol. 2001;18:789-797.
85. Robin C, Trieger N. Paradoxical reactions to benzodiazepines in intravenous sedation: A report of 2 cases and review of the literature. Anesth Prog. 2002;49:128-132.
86. Sanders JC. Flumazenil reverses a paradoxical reaction to intravenous midazolam in a child with uneventful prior exposure to midazolam. Paediatr Anaesth. 2003;13:369-370.
87. Graae F, Milner J, Rizzotto L, Klein RG. Clonazepam in childhood anxiety disorders. J Am Acad Child Adolesc Psychiatry. 1994;33:372-376.
88. Salzman C, DiMascio A, Shader RI, Harmatz JS. Chlordiazepoxide, expectation and hostility. Psychopharmacologia. 1969;14:38-45.
89. Kochansky GE, Salzman C, Shader RI, Harmatz JS, Ogeltree AM. The differential effects of chlordiazepoxide and oxazepam on hostility in a small group setting. Am J Psychiatry. 1975;132:861-863.
90. Cherek DR, Spiga R, Roache JD, Cowan KA. Effects of triazolam on human aggressive, escape and point-maintained responding. Pharmacol Biochem Behav. 1991;40:835-839.
91. Fillmore MT, Rush CR, Kelly TH, Hays L. Triazolam impairs inhibitory control of behavior in humans. Exp Clin Psychopharmacol. 2001;9:363-371.
92. Dowd SM, Strong MJ, Janicak PG, Negrusz A. The behavioral and cognitive effects of two benzodiazepines associated with drug-facilitated sexual assault. J Forensic Sci. 2002;47:1101-1107.
93. Edwards RA, Medlicott RW. Advantages and disadvantages of benzodiazepine prescription. NZ Med J. 1980;92:357-359.
94. Roy-Byrne PP, Craske MG, Stein MB, Sullivan G, Bystritsky A, Katon W, Golinelli D, Sherbourne CD. A randomized effectiveness trial of cognitive-behavioral therapy and medication for primary care panic disorder. Arch Gen Psychiatry. 2005;62:290-298.
95. Hawkridge SM, Stein DJ. A risk-benefit assessment of pharmacotherapy for anxiety disorders in children and adolescents. Drug Saf. 1998;19:283-297.
96. Alexander AD. Evaluation of an ataractic (hydroxyzine) in 2025 patients as an adjunct in oral surgery. WV Dent J. 1960;34:56-59.
97. Tornetta FJ. A comparison of droperidol, diazepam, and hydroxyzine hydrochloride as premedication. Anesth Analg. 1977;56:496-500.
98. Herr GP, Conner JT, Schehl D, Dorey F. Comparison of IM diazepam and hydroxyzine as premedicants. Br J Anaes. 1982;54:3-9.
99. Garber R. Management of tension and anxiety states with hydroxyzine hydrochloride. J Fla Med Assoc. 1958;45:549-552.
100. Lipton MI. High dosages of hydroxyzine in out-patient treatment of severe neuroses and psychoses. Pa Med J. 1961;64:60-62.
101. Shalowitz M. Evaluation of an ataraxic (hydroxyzine) in long-term therapy. Int Rec Med. 1961;174:357-361.
102. Breslow L. Evaluation of hydroxyzine pamoate concentration as an ataractic. Curr Ther Res. 1968;10:421-427.
103. Rickels K, Gordon PE, Zamostien BB, Case W, Hutchison J, Chung H. Hydroxyzine and chlordiazepoxide in anxious neurotic outpatients: A collaborative controlled study. Compr Psychiatry. 1970;11:457-474.
104. Goldberg HL, Finnerty RJ. The use of hydroxyzine (Vistaril) in the treatment of anxiety neurosis. Psychosomatics. 1973;14:38-41.
105. Darcis T, Ferreri M, Natens J, Burtin B, Deram P. A multicentre double-blind placebo-controlled study investigating the anxiolytic efficacy of hydroxyzine in patients with generalized anxiety. Hum Psychopharmacol. 1995;10:181-187.
106. Lader M, Scotto JC. A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl). 1998;139:402-406.
107. Llorca PM, Spadone C, Sol O, Danniau A, Bougerol T, Corruble E, Faruch M, Macher JP, Sermet E, Servant D. Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: A 3-month double-blind study. J Clin Psychiatry. 2002;63:1020-1027.
108. Roy-Byrne PP, Ward NG, Donnelly PJ. Valproate in anxiety and withdrawal syndromes. J Clin Psychiatry. 1989;50(Suppl): 44-48.
109. Primeau F, Fontaine R, Beauclair L. Valproic acid and panic disorder. Can J Psychiatry. 1990; 35:248-250.
110. Lum M, Fontaine R, Elie R, Ontiveros A. Probable interaction of sodium divalproex with benzodiazepines. Prog Neuropsychopharmacol Biol Psychiatry. 1991;15:269-273.
111. Woodman CL, Noyes Jr R. Panic disorder: treatment with valproate. J Clin Psychiatry. 1994;55:134-136.
112. Rosenthal M. Tiagabine for the treatment of generalized anxiety disorder: A randomized, open-label, clinical trial with paroxetine as a positive control. J Clin Psychiatry. 2003;64:1245-1249.
113. Crane D. Tiagabine for the treatment of anxiety. Depress Anxiety. 2003;18:51-52.
114. Schwartz TL, Azhar N, Husain J, Nihalani N, Simionescu M, Coovert D, Jindal S, Tirmazi S. An open-label study of tiagabine as augmentation therapy for anxiety. Ann Clin Psychiatry. 2005;17:167-172.
115. Pollack MH, Roy-Byrne PP, Van Ameringen M, Snyder H, Brown C, Ondrasik J, Rickels K. The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: Results of a placebo-controlled study. J Clin Psychiatry. 2005;66:1401-1408.
116. Carpenter LL, Schecter JM, Tyrka AR, Mello AF, Mello MF, Haggarty R, Price LH. Open-label tiagabine monotherapy for major depressive disorder with anxiety. J Clin Psychiatry. 2006;67:66-71.
117. Chouinard G, Beauclair L, Belanger MC. Gabapentin: Long-term anti-anxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. Can J Psychiatry. 1998;43:305.
118. Pande AC, Pollack MH, Crockatt J, Greiner M, Chouinard G, Lydiard RB, Taylor CB, Dager SR, Shiovitz T. Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol. 2000;20:467-471.
119. Feltner DE, Crockatt JG, Dubovsky SJ, Cohn CK, Shrivastava RK, Targum SD, Liu-Dumaw M, Carter CM, Pande AC. A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol. 2003;23:240-249.
120. Pande AC, Crockatt JG, Feltner DE, Janney CA, Smith WT, Weisler R, Londborg PD, Bielski RJ, Zimbroff DL, Davidson JR, Liu-Dumaw M. Pregabalin in generalized anxiety disorder: A placebo-controlled trial. Am J Psychiatry. 2003;160:533-540.
121. Rickels K, Pollack MH, Feltner DE, Lydiard RB, Zimbroff DL, Bielski RJ, Tobias K, Brock JD, Zornberg GL, Pande AC. Pregabalin for treatment of generalized anxiety disorder: A 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry. 2005;62:1022-1030.
122. Pohl RB, Feltner DE, Fieve RR, Pande AC. Efficacy of pregabalin in the treatment of generalized anxiety disorder: Double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol. 2005;25:151-158.
123. Frampton JE, Foster RH. Pregabalin: In the treatment of generalized anxiety disorder. CNS Drugs. 2006;20:685-693; discussion 694-695.
124. Montgomery SA, Tobias K, Zornberg GL, Kasper S, Pande AC. Efficacy and safety of pregabalin in the treatment of generalized anxiety disorder: A 6-week, multicenter, randomized, double-blind, placebo-controlled comparison of pregabalin and venlafaxine. J Clin Psychiatry. 2006;67:771-782.
125. Stein DJ. Pregabalin and venlafaxine improve symptoms of generalized anxiety disorder. Evid Based Ment Health. 2007;10:23.
126. Adson DE, Kushner MG, Eiben KM, Schulz SC. Preliminary experience with adjunctive quetiapine in patients receiving selective serotonin reuptake inhibitors. Depress Anxiety. 2004;19:121-126.
127. Kasper S. Quetiapine is effective against anxiety and depressive symptoms in long-term treatment of patients with schizophrenia. Depress Anxiety. 2004;20:44-47.
128. Hirschfeld RM, Weisler RH, Raines SR, Macfadden W. Quetiapine in the treatment of anxiety in patients with bipolar I or II depression: A secondary analysis from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006;67: 355-362.
129. Galynker I, Khan A, Grebchenko Y, Ten A, Malaya L, Yanowitch P, Cohen LJ. Low-dose risperidone and quetiapine as monotherapy for comorbid anxiety and depression. J Clin Psychiatry. 2005;66:544.
130. Tollefson GD, Sanger TM. Anxious-depressive symptoms in schizophrenia: A new treatment target for pharmacotherapy? Schizophr Res. 1999;35(Suppl):S13-21.
131. Mintzer J, Faison W, Street JS, Sutton VK, Breier A. Olanzapine in the treatment of anxiety symptoms due to Alzheimer's disease: A post hoc analysis. Int J Geriatr Psychiatry. 2001;16(Suppl 1):S71-77.
132. Tohen M, Vieta E, Calabrese J, Ketter TA, Sachs G, Bowden C, Mitchell PB, Centorrino F, Risser R, Baker RW, Evans AR, Beymer K, Dube S, Tollefson GD, Breier A. Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression. Arch Gen Psychiatry. 2003;60: 1079-1088.
133. Littrell KH, Petty RG, Hilligoss NM, Kirshner CD, Johnson CG. The effect of olanzapine on anxiety among patients with schizophrenia: Preliminary findings. J Clin Psychopharmacol. 2003;23:523-525.
134. Hollifield M, Thompson PM, Ruiz JE, Uhlenhuth EH. Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety. 2005;21:33-40.
135. Pollack MH, Simon NM, Zalta AK, Worthington JJ, Hoge EA, Mick E, Kinrys G, Oppenheimer J. Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder: A placebo controlled study. Biol Psychiatry. 2006;59:211-215.
136. Blin O, Azorin JM, Bouhours P. Antipsychotic and anxiolytic properties of risperidone, haloperidol, and methotrimeprazine in schizophrenic patients. J Clin Psychopharmacol. 1996;16:38-44.
137. Brawman-Mintzer O, Knapp RG, Nietert PJ. Adjunctive risperidone in generalized anxiety disorder: A double-blind, placebo-controlled study. J Clin Psychiatry. 2005;66:1321-1325.
138. Simon NM, Hoge EA, Fischmann D, Worthington JJ, Christian KM, Kinrys G, Pollack MH. An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry. 2006;67:381-385.
139. Snyderman SH, Rynn MA, Rickels K. Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol. 2005;25:497-499.
140. Worthington JJ III, Kinrys G, Wygant LE, Pollack MH. Aripiprazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol. 2005;20:9-11.
141. Adson DE, Kushner MG, Fahnhorst TA. Treatment of residual anxiety symptoms with adjunctive aripiprazole in depressed patients taking selective serotonin reuptake inhibitors. J Affect Disord. 2005;86:99-104.
142. Calabrese JR, Delucchi GA. Spectrum of efficacy of valproate in 55 patients with rapid-cycling bipolar disorder. Am J Psychiatry. 1990;147:431-434.
143. Davis LL, Kabel D, Patel D, Choate AD, Foslien-Nash C, Gurguis GN, Kramer GL, Petty F. Valproate as an antidepressant in major depressive disorder. Psychopharmacol Bull. 1996;32: 647-652.
144. Emsley RA, Buckley P, Jones AM, Greenwood MR. Differential effect of quetiapine on depressive symptoms in patients with partially responsive schizophrenia. J Psychopharmacol. 2003;17:210-215.
145. Papakostas GI, Petersen TJ, Nierenberg AA, Murakami JL, Alpert JE, Rosenbaum JF, Fava M. Ziprasidone augmentation of selective serotonin reuptake inhibitors (SSRIs) for SSRI-resistant major depressive disorder. J Clin Psychiatry. 2004;65:217-221.
146. Barbee JG, Conrad EJ, Jamhour NJ. Aripiprazole augmentation in treatment-resistant depression. Ann Clin Psychiatry. 2004;16:189-194.
147. Simon JS, Nemeroff CB. Aripiprazole augmentation of antidepressants for the treatment of partially responding and nonresponding patients with major depressive disorder. J Clin Psychiatry. 2005;66:1216-1220.
148. Vanelle JM, Douki S. A double-blind randomised comparative trial of amisulpride versus olanzapine for 2 months in the treatment of subjects with schizophrenia and comorbid depression. Eur Psychiatry. 2006;21:523-530.
149. Mathews J, Garcia KS, Mintun MA, Sheline YI. Antidepressant efficacy of olanzapine as monotherapy in major depressive disorder, without psychosis: A pilot study. Psychiatry Res. 2006;146:149-155.
150. Sagud M, Mihaljevic-Peles A, Muck-Seler D, Jakovljevic M, Pivac N. Quetiapine augmentation in treatment-resistant depression: A naturalistic study. Psychopharmacology (Berl). 2006;187:511-514.
151. Doree JP, Des Rosiers J, Lew V, Gendron A, Elie R, Stip E, Tourjman SV. Quetiapine augmentation of treatment-resistant depression: A comparison with lithium. Curr Med Res Opin. 2007;23:333-341.
152. Meltzer HY, Okayli G. Reduction of suicidality during clozapine treatment of neuroleptic-resistant schizophrenia: Impact on risk-benefit assessment. Am J Psychiatry. 1995;152:183-190.
153. Keck PE, Jr., Strakowski SM, McElroy SL. The efficacy of atypical antipsychotics in the treatment of depressive symptoms, hostility, and suicidality in patients with schizophrenia. J Clin Psychiatry. 2000;61(Suppl 3):4-9.
154. Meltzer HY, Alphs L, Green AI, Altamura AC, Anand R, Bertoldi A, Bourgeois M, Chouinard G, Islam MZ, Kane J, Krishnan R, Lindenmayer JP, Potkin S. Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry. 2003;60:82-91.
155. Barak Y, Mirecki I, Knobler HY, Natan Z, Aizenberg D. Suicidality and second generation antipsychotics in schizophrenia patients: A case-controlled retrospective study during a 5-year period. Psychopharmacology (Berl). 2004;175:215-219.
156. Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: A retrospective database study. Clin Ther. 2006;28:1912-1921.
157. Dannon PN, Gon-Usishkin M, Gelbert A, Lowengrub K, Grunhaus L. Cognitive behavioral group therapy in panic disorder patients: The efficacy of CBGT versus drug treatment. Ann Clin Psychiatry. 2004;16:41-46.
158. Azhar MZ: Comparison of fluvoxamine alone, fluvoxamine and cognitive psychotherapy and psychotherapy alone in the treatment of panic disorder in Kelantan - implications for management by family doctors. Med J Malaysia. 2000;55:402-408.
159. Clark DM, Salkovskis PM, Hackmann A, Middleton H, Anastasiades P, Gelder M. A comparison of cognitive therapy, applied relaxation and imipramine in the treatment of panic disorder. Br J Psychiatry. 1994;164:759-769.
160. Breier A, Meehan K, Birkett M, David S, Ferchland I, Sutton V, Taylor CC, Palmer R, Dossenbach M, Kiesler G, Brook S, Wright P: A double-blind, placebo-controlled dose-response comparison of intramuscular olanzapine and haloperidol in the treatment of acute agitation in schizophrenia. Arch Gen Psychiatry. 2002;59:441-448.
161. Ost LG, Westling BE. Applied relaxation vs. cognitive behavior therapy in the treatment of panic disorder. Behav Res Ther. 1995;33:145-158.
162. Ost LG, Westling BE, Hellstrom K. Applied relaxation, exposure in vivo and cognitive methods in the treatment of panic disorder with agoraphobia. Behav Res Ther. 1993;31:383-394.
163. Taylor CB, Kenigsberg ML, Robinson JM. A controlled comparison of relaxation and diazepam in panic disorder. J Clin Psychiatry. 1982;43:423-425.
164. Dhossche DM. Toxicology of suicide: Touchstone for suicide prevention? Med Sci Monit. 2003;9:SR9-SR19.
165. Boyle D, Tobin JM. Pharmaceutical management of behavior disorders. J Med Soc NJ. 1961;58:427-429.
166. Feldman PE. An analysis of the efficacy of diazepam. J Neuropsych. 1962;5(Suppl 1):S62-67.
167. Zucker HS. Strange behavior with oxazepam. NY State J Med. 1972;72:974.
168. Lion JR, Azcarate CL, Koepke HH. "Paradoxical rage reactions" during psychotropic medication. Dis Nerv Syst. 1975;36:557-558.
169. Goldney RD. Paradoxical reaction to a new minor tranquilizer. Med J Aust. 1977;1:139-140.
170. Zisook S, DeVaul RA. Adverse behavioral effects of benzodiazepines. J Fam Pract. 1977;5:963-966.
171. Gardos G. Disinhibition of behavior by antianxiety drugs. Psychosomatics. 1980;21:1025-1026.
172. Rosenbaum JF, Woods SW, Groves JE, Klerman GL. Emergence of hostility during alprazolam treatment. Am J Psychiatry. 1984;141:792-793.
173. Strahan A, Rosenthal J, Kaswan M, Winston A. Three case reports of acute paroxysmal excitement associated with alprazolam treatment. Am J Psychiatry. 1985;142:859-861.
174. Binder RL. Three case reports of behavioral disinhibition with clonazepam. Gen Hosp Psychiatry. 1987;9:151-153.
175. Kubacki A. Sexual disinhibition on clonazepam. Can J Psychiatry. 1987;32:643-645.
176. Marrosu F, Marrosu G, Rachel MG, Biggio G. Paradoxical reactions elicited by diazepam in children with classic autism. Funct Neurol. 1987;2:355-361.
177. Marchevsky S, Isaacs G, Nitzan I. Behavioral disinhibition with clonazepam. Gen Hosp Psychiatry. 1988;10:447.
178. Fava M, Borofsky GF. Sexual disinhibition during treatment with a benzodiazepine: A case report. Int J Psychiatry Med. 1991;21:99-104.